$VTVT
vTv Therapeutics Inc.

2017 Q4 Form 10-K Financial Statement

#000156459018003515 Filed on February 27, 2018

View on sec.gov

Income Statement

Concept 2017 Q4 2017 Q3 2017 Q2
Revenue $233.0K $15.00K $13.00K
YoY Change 513.16% -60.53% -92.86%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.940M $2.570M $3.010M
YoY Change 30.67% 7.08% 12.73%
% of Gross Profit
Research & Development $10.07M $8.989M $9.623M
YoY Change -9.28% -19.53% -20.32%
% of Gross Profit
Depreciation & Amortization $50.00K $50.00K $50.00K
YoY Change 0.0% -28.57% -28.57%
% of Gross Profit
Operating Expenses $13.01M $11.56M $12.63M
YoY Change -2.55% -14.84% -14.8%
Operating Profit -$12.77M -$11.54M -$12.62M
YoY Change -4.06% -14.69% -13.83%
Interest Expense -$830.0K -$810.0K $832.0K
YoY Change 124.32% -4150.0% 83100.0%
% of Operating Profit
Other Income/Expense, Net -$190.0K $0.00 $0.00
YoY Change 850.0% -100.0% -100.0%
Pretax Income -$13.79M -$12.36M -$13.41M
YoY Change 0.58% -8.51% -8.23%
Income Tax -$5.050M $0.00 $0.00
% Of Pretax Income
Net Earnings -$4.311M -$3.650M -$3.963M
YoY Change 6.44% -8.59% -11.08%
Net Earnings / Revenue -1850.21% -24333.33% -30484.62%
Basic Earnings Per Share
Diluted Earnings Per Share -$444.8K -$376.7K -$408.7K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q4 2017 Q3 2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $11.80M $20.50M $32.50M
YoY Change -77.09% -59.88% -49.06%
Cash & Equivalents $11.76M $20.77M $32.51M
Short-Term Investments
Other Short-Term Assets $600.0K $1.000M $600.0K
YoY Change 0.0% -9.09% 50.0%
Inventory
Prepaid Expenses
Receivables $8.000M $0.00 $0.00
Other Receivables $0.00
Total Short-Term Assets $20.36M $21.50M $33.15M
YoY Change -60.93% -58.73% -48.41%
LONG-TERM ASSETS
Property, Plant & Equipment $283.0K $300.0K $374.0K
YoY Change -36.26% -40.0% -33.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $2.500M
YoY Change
Other Assets $4.800M $2.300M $2.253M
YoY Change 148.19% 9.52% 16.49%
Total Long-Term Assets $7.555M $2.600M $2.627M
YoY Change 217.7% 0.0% 4.29%
TOTAL ASSETS
Total Short-Term Assets $20.36M $21.50M $33.15M
Total Long-Term Assets $7.555M $2.600M $2.627M
Total Assets $27.92M $24.10M $35.78M
YoY Change -48.77% -55.94% -46.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.269M $10.10M $10.70M
YoY Change -25.85% -4.72% 9.18%
Accrued Expenses
YoY Change
Deferred Revenue $8.757M
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $4.300M $2.100M $500.0K
YoY Change
Total Short-Term Liabilities $26.93M $12.20M $11.26M
YoY Change 135.52% 15.09% 14.58%
LONG-TERM LIABILITIES
Long-Term Debt $15.30M $17.20M $18.50M
YoY Change 37.84%
Other Long-Term Liabilities $290.0K $300.0K $273.0K
YoY Change -33.03% 50.0% 36.5%
Total Long-Term Liabilities $290.0K $17.50M $273.0K
YoY Change -33.03% 8650.0% 36.5%
TOTAL LIABILITIES
Total Short-Term Liabilities $26.93M $12.20M $11.26M
Total Long-Term Liabilities $290.0K $17.50M $273.0K
Total Liabilities $47.52M $160.4M $30.04M
YoY Change 107.3% -3.37% 198.86%
SHAREHOLDERS EQUITY
Retained Earnings -$279.1M -$232.8M
YoY Change 29.5% 15.26%
Common Stock $127.7M $126.1M
YoY Change 2.79% 3.23%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$151.0M -$136.3M -$106.4M
YoY Change
Total Liabilities & Shareholders Equity $27.92M $24.10M $35.78M
YoY Change -48.77% -55.94% -46.42%

Cashflow Statement

Concept 2017 Q4 2017 Q3 2017 Q2
OPERATING ACTIVITIES
Net Income -$4.311M -$3.650M -$3.963M
YoY Change 6.44% -8.59% -11.08%
Depreciation, Depletion And Amortization $50.00K $50.00K $50.00K
YoY Change 0.0% -28.57% -28.57%
Cash From Operating Activities -$6.330M -$11.78M -$12.63M
YoY Change -44.62% -7.39% 9.26%
INVESTING ACTIVITIES
Capital Expenditures -$20.00K $0.00 $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $30.00K $0.00
YoY Change
Cash From Investing Activities -$20.00K $30.00K $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 0.000
YoY Change -100.0% -100.0% -100.0%
NET CHANGE
Cash From Operating Activities -6.330M -11.78M -12.63M
Cash From Investing Activities -20.00K 30.00K 0.000
Cash From Financing Activities 0.000 0.000 0.000
Net Change In Cash -6.350M -11.75M -12.63M
YoY Change -1543.18% -8.06% 8.32%
FREE CASH FLOW
Cash From Operating Activities -$6.330M -$11.78M -$12.63M
Capital Expenditures -$20.00K $0.00 $0.00
Free Cash Flow -$6.310M -$11.78M -$12.63M
YoY Change -44.79% -7.39% 10.11%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017 dei Trading Symbol
TradingSymbol
VTVT
CY2017 dei Entity Registrant Name
EntityRegistrantName
vTv Therapeutics Inc.
CY2017 dei Entity Central Index Key
EntityCentralIndexKey
0001641489
CY2017 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2017 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
CY2017 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2017 dei Document Period End Date
DocumentPeriodEndDate
2017-12-31
CY2017 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2017 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2017 dei Amendment Flag
AmendmentFlag
false
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P3Y
CY2016 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-39001000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-16144000
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-16352000
CY2015 us-gaap Profit Loss
ProfitLoss
-41107000
CY2015 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-13609000
CY2017 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2017 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
26929000
CY2017Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
15316000
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
442000
CY2017Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
4497000
CY2017Q4 us-gaap Due To Related Parties Noncurrent
DueToRelatedPartiesNoncurrent
492000
CY2017Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
290000
CY2016Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
433000
CY2017Q4 us-gaap Liabilities
Liabilities
47524000
CY2016Q4 us-gaap Liabilities
Liabilities
22925000
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
131440000
CY2016Q4 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
122515000
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
127682000
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
124212000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-279058000
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-215486000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-151047000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
27917000
CY2017 us-gaap Sales Revenue Net
SalesRevenueNet
291000
CY2016 us-gaap Sales Revenue Net
SalesRevenueNet
634000
CY2015 us-gaap Sales Revenue Net
SalesRevenueNet
519000
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
39640000
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
44953000
CY2016 vtvt Research And Development Expense Related Party
ResearchAndDevelopmentExpenseRelatedParty
795000
CY2015 vtvt Research And Development Expense Related Party
ResearchAndDevelopmentExpenseRelatedParty
2347000
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9906000
CY2017 us-gaap Investment Income Interest
InvestmentIncomeInterest
117000
CY2016 us-gaap Investment Income Interest
InvestmentIncomeInterest
87000
CY2015 us-gaap Investment Income Interest
InvestmentIncomeInterest
40000
CY2017 us-gaap Interest Expense
InterestExpense
3092000
CY2016 us-gaap Interest Expense
InterestExpense
398000
CY2015 us-gaap Interest Expense
InterestExpense
108000
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
800000
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2017 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-38503000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
-498806000
CY2015 vtvt Net Income Loss Prior To Reorganization Transactions
NetIncomeLossPriorToReorganizationTransactions
-22111000
CY2015 vtvt Effect Of Reorganization Transactions In Value
EffectOfReorganizationTransactionsInValue
596244000
CY2015 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
104445000
CY2015 vtvt Net Income Loss Subsequent To Reorganization Transactions
NetIncomeLossSubsequentToReorganizationTransactions
-5387000
CY2015 us-gaap Minority Interest Change In Redemption Value
MinorityInterestChangeInRedemptionValue
-190598000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
-77970000
CY2017Q4 us-gaap Long Term Investments
LongTermInvestments
2480000
CY2017Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
2292000
CY2016Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
1934000
CY2017Q4 us-gaap Assets
Assets
27917000
CY2016Q4 us-gaap Assets
Assets
54495000
CY2017Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
13901000
CY2016Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
11413000
CY2017Q4 us-gaap Notes Payable Current
NotesPayableCurrent
4271000
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-27498000
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
612000
CY2017Q2 dei Entity Public Float
EntityPublicFloat
33577419
CY2017Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
162000
CY2017Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
8000000
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
444000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11758000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
20362000
CY2017Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
2500000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
283000
CY2016Q4 us-gaap Assets Current
AssetsCurrent
52117000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
51505000
CY2016Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
11058000
CY2017Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
8757000
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
21000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11434000
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11333000
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-50682000
CY2017 us-gaap Operating Expenses
OperatingExpenses
50973000
CY2016 us-gaap Operating Expenses
OperatingExpenses
55654000
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-55020000
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
-38142000
CY2016 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-22000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-41107000
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2015 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
1667000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-55353000
CY2016 us-gaap Profit Loss
ProfitLoss
-55353000
CY2017 us-gaap Profit Loss
ProfitLoss
-54647000
CY2015 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-838000
CY2017 vtvt Other Income Expenses Related Party
OtherIncomeExpensesRelatedParty
-190000
CY2015 vtvt Other Income Expenses Related Party
OtherIncomeExpensesRelatedParty
-392000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-53847000
CY2015 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9077000
CY2015 us-gaap Operating Expenses
OperatingExpenses
38661000
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27237000
CY2017 dei Document Type
DocumentType
10-K
CY2015 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
12461000
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
859000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
-90945000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
54495000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-44560000
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
87000
CY2016 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-83000
CY2016 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
19000
CY2016 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-48209000
CY2016 us-gaap Proceeds From Sales Of Assets Investing Activities
ProceedsFromSalesOfAssetsInvestingActivities
4000
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
104000
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-79000
CY2015 us-gaap Increase Decrease In Notes Receivables
IncreaseDecreaseInNotesReceivables
20000
CY2016 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
4786000
CY2015 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2930000
CY2015 vtvt Increase Decrease In Accounts Payable And Accrued Liabilities Related Parties
IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedParties
2458000
CY2015 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
219000
CY2017 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
24000
CY2015 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-871000
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-36946000
CY2017 us-gaap Proceeds From Sales Of Assets Investing Activities
ProceedsFromSalesOfAssetsInvestingActivities
32000
CY2015 us-gaap Proceeds From Sales Of Assets Investing Activities
ProceedsFromSalesOfAssetsInvestingActivities
25000
CY2016 vtvt Increase Decrease In Accounts Payable And Accrued Liabilities Related Parties
IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedParties
-880000
CY2017 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
10753000
CY2014Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1384000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14420000
CY2015 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
12461000
CY2017 vtvt Change In Fair Value Of Warrants Related Party
ChangeInFairValueOfWarrantsRelatedParty
190000
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2641000
CY2016 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
721000
CY2016 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
3164000
CY2016 us-gaap Minority Interest Change In Redemption Value
MinorityInterestChangeInRedemptionValue
-3149000
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3645000
CY2017 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
167000
CY2017 vtvt Adjustments To Additional Paid In Capital Letter Agreement And Warrants Issued To Related Party
AdjustmentsToAdditionalPaidInCapitalLetterAgreementAndWarrantsIssuedToRelatedParty
342000
CY2017 us-gaap Minority Interest Change In Redemption Value
MinorityInterestChangeInRedemptionValue
-47428000
CY2017 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
11000
CY2016 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
2000
CY2015 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
7000
CY2017 us-gaap Depreciation
Depreciation
197000
CY2016 us-gaap Depreciation
Depreciation
265000
CY2015 us-gaap Depreciation
Depreciation
501000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
3645000
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
2641000
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
859000
CY2015 vtvt Change In Fair Value Of Contingent Distribution
ChangeInFairValueOfContingentDistribution
695000
CY2017 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1029000
CY2016 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
154000
CY2015 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
27000
CY2015 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
48000
CY2015 vtvt Bad Debt Expense Recovery Related Party
BadDebtExpenseRecoveryRelatedParty
-3000
CY2017 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
8000000
CY2016 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-69000
CY2015 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
69000
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-170000
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-502000
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1020000
CY2016 us-gaap Increase Decrease In Due From Employee Current
IncreaseDecreaseInDueFromEmployeeCurrent
-49000
CY2015 us-gaap Increase Decrease In Due From Employee Current
IncreaseDecreaseInDueFromEmployeeCurrent
-12000
CY2017 vtvt Increase Decrease In Long Term Deposits
IncreaseDecreaseInLongTermDeposits
358000
CY2016 vtvt Increase Decrease In Long Term Deposits
IncreaseDecreaseInLongTermDeposits
261000
CY2015 vtvt Increase Decrease In Long Term Deposits
IncreaseDecreaseInLongTermDeposits
1598000
CY2017 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2448000
CY2016 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-198000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
57000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-25000
CY2015 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
105773000
CY2017 us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
7500000
CY2016 us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
12500000
CY2016 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
673000
CY2015 vtvt Payment Of Offering Cost Related Party
PaymentOfOfferingCostRelatedParty
1329000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
7500000
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-37085000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51505000
CY2015Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
88003000
CY2015 us-gaap Interest Paid
InterestPaid
75000
CY2017 vtvt Receipt Of Investment Partial Consideration For License Agreement
ReceiptOfInvestmentPartialConsiderationForLicenseAgreement
2480000
CY2015 us-gaap Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1
NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
2747000
CY2016 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
3164000
CY2017 vtvt Issuance Of Letter Agreement And Warrants To Purchase Common Stock To Related Party
IssuanceOfLetterAgreementAndWarrantsToPurchaseCommonStockToRelatedParty
302000
CY2016 vtvt Issuance Of Warrants To Purchase Of Common Stock
IssuanceOfWarrantsToPurchaseOfCommonStock
923000
CY2015 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
19289000
CY2016 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
33000
CY2015 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
89000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
11794000
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
123644000
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-36498000
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
86619000
CY2017 us-gaap Interest Paid
InterestPaid
2064000
CY2016 us-gaap Interest Paid
InterestPaid
242000
CY2017 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On an ongoing basis, the Company evaluates its estimates, including those related to the grant date fair value of equity awards, the fair value of warrants to purchase shares of its Class A Common Stock, the fair value of the Class B Common Stock, the useful lives of property and equipment, the fair value of the Company&#8217;s membership units, the fair value of redeemable preferred units, and the fair value of the Company&#8217;s debt, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities.</p></div>
CY2017 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with multiple financial institutions. The balances of these cash accounts frequently exceed insured limits.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable as of December 31, 2017, consisted entirely of the upfront payment due in connection with the <font style="color:#000000;">License Agreement with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (&#8220;Huadong&#8221;) (the &#8220;Huadong License Agreement&#8221;) which was fully received in January 2018</font>.&nbsp;&nbsp;There were no accounts receivable at December 31, 2016.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Four customers represented 100% of the revenue earned during the year ended December 31, 2017.&nbsp;&nbsp;Two customers represented 100% of the revenue earned during the years ended December 31, 2016 and 2015. </p></div>
CY2016Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0
CY2016Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
0
CY2017Q4 us-gaap Assets Of Disposal Group Including Discontinued Operation
AssetsOfDisposalGroupIncludingDiscontinuedOperation
0
CY2016Q4 us-gaap Assets Of Disposal Group Including Discontinued Operation
AssetsOfDisposalGroupIncludingDiscontinuedOperation
0
CY2017 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2017 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P3Y
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3645000
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2641000
CY2015 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
859000
CY2017 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
CY2016 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1096101
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
882000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
17369
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1960732
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
716787
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y9M18D
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
1906322
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P8Y4M24D
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.68
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.77
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.95
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.50
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
10.84
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
8.57
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9399000
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
10898000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
9116000
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
10454000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2269000
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3060000
CY2017Q4 vtvt Accrued Development Costs Current
AccruedDevelopmentCostsCurrent
8586000
CY2016Q4 vtvt Accrued Development Costs Current
AccruedDevelopmentCostsCurrent
6305000
CY2017Q4 vtvt Accrued Payroll Costs Current
AccruedPayrollCostsCurrent
1641000
CY2016Q4 vtvt Accrued Payroll Costs Current
AccruedPayrollCostsCurrent
1468000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1405000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
580000
CY2017Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
20000000
CY2016Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
12500000
CY2017Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
413000
CY2016Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
1442000
CY2017Q4 us-gaap Notes Payable
NotesPayable
19587000
CY2016Q4 us-gaap Notes Payable
NotesPayable
11058000
CY2017Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
4271000
CY2017Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
10000000
CY2017Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
5729000
CY2017 us-gaap Description Of Lessee Leasing Arrangements Operating Leases
DescriptionOfLesseeLeasingArrangementsOperatingLeases
operating leases expiring at various dates through 2019
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
365000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
371000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
736000
CY2017Q4 us-gaap Asset Retirement Obligations Noncurrent
AssetRetirementObligationsNoncurrent
200000
CY2016Q4 us-gaap Asset Retirement Obligations Noncurrent
AssetRetirementObligationsNoncurrent
200000
CY2015Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2015Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2017 us-gaap Common Stock Voting Rights
CommonStockVotingRights
Holders of Class A Common Stock and Class B Common Stock will be entitled to one vote for each share held on all matters submitted to stockholders for their vote or approval.
CY2017 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
200000
CY2017Q4 vtvt Redeemable Noncontrolling Interest Temporary Equity Redemption Value
RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue
131400000
CY2016Q4 vtvt Redeemable Noncontrolling Interest Temporary Equity Redemption Value
RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue
122500000
CY2017 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.50
CY2017 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.06
CY2017 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
100000
CY2016 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
200000
CY2015 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
100000
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35
CY2017 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
5847000
CY2017 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-18846000
CY2016 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-19374000
CY2015 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-14387000
CY2017 vtvt Income Tax Reconciliation Partnership Income Federal Not Subject To Tax
IncomeTaxReconciliationPartnershipIncomeFederalNotSubjectToTax
13475000
CY2017Q1 us-gaap Profit Loss
ProfitLoss
-14286000
CY2016 vtvt Income Tax Reconciliation Partnership Income Federal Not Subject To Tax
IncomeTaxReconciliationPartnershipIncomeFederalNotSubjectToTax
13651000
CY2015 vtvt Income Tax Reconciliation Partnership Income Federal Not Subject To Tax
IncomeTaxReconciliationPartnershipIncomeFederalNotSubjectToTax
12502000
CY2015 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2017Q2 us-gaap Profit Loss
ProfitLoss
-13414000
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-3993000
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
-4050000
CY2017 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
9504000
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
10036000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
9504000
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
10036000
CY2017 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-500000
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2017Q4 us-gaap Significant Change In Unrecognized Tax Benefits Is Reasonably Possible Amount Of Unrecorded Benefit
SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit
0
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
27786936
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
24367927
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
24627748
CY2017Q1 us-gaap Sales Revenue Net
SalesRevenueNet
30000
CY2017Q2 us-gaap Sales Revenue Net
SalesRevenueNet
13000
CY2017Q3 us-gaap Sales Revenue Net
SalesRevenueNet
15000
CY2017Q4 us-gaap Sales Revenue Net
SalesRevenueNet
233000
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-13754000
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-12615000
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-11541000
CY2016 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2017Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-12772000
CY2017 vtvt Income Tax Reconciliation Foreign Withholding Tax
IncomeTaxReconciliationForeignWithholdingTax
800000
CY2017 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
55000
CY2017 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-531000
CY2016 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
5723000
CY2015 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
1885000
CY2017 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.015
CY2016 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2015 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
9023000
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
8189000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3000
CY2017Q4 us-gaap Deferred Tax Assets Investments
DeferredTaxAssetsInvestments
470000
CY2016Q4 us-gaap Deferred Tax Assets Investments
DeferredTaxAssetsInvestments
1844000
CY2017Q4 us-gaap Deferred Tax Assets Charitable Contribution Carryforwards
DeferredTaxAssetsCharitableContributionCarryforwards
11000
CY2017Q3 us-gaap Profit Loss
ProfitLoss
-12355000
CY2017Q4 us-gaap Profit Loss
ProfitLoss
-14592000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-4220000
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-3963000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-3650000
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
-4311000
CY2016Q1 us-gaap Sales Revenue Net
SalesRevenueNet
376000
CY2016Q2 us-gaap Sales Revenue Net
SalesRevenueNet
182000
CY2016Q3 us-gaap Sales Revenue Net
SalesRevenueNet
38000
CY2016Q4 us-gaap Sales Revenue Net
SalesRevenueNet
38000
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-13540000
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-14639000
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-13528000
CY2016Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-13313000
CY2016Q1 us-gaap Profit Loss
ProfitLoss
-13520000
CY2016Q2 us-gaap Profit Loss
ProfitLoss
-14617000
CY2016Q3 us-gaap Profit Loss
ProfitLoss
-13505000
CY2016Q4 us-gaap Profit Loss
ProfitLoss
-13711000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-3852000
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-4457000
CY2017Q4 us-gaap Fair Value Equity Level1 To Level2 Transfers Amount
FairValueEquityLevel1ToLevel2TransfersAmount
0
CY2016Q4 us-gaap Fair Value Equity Level1 To Level2 Transfers Amount
FairValueEquityLevel1ToLevel2TransfersAmount
0
CY2015Q4 us-gaap Fair Value Equity Level1 To Level2 Transfers Amount
FairValueEquityLevel1ToLevel2TransfersAmount
0

Files In Submission

Name View Source Status
0001564590-18-003515-index-headers.html Edgar Link pending
0001564590-18-003515-index.html Edgar Link pending
0001564590-18-003515.txt Edgar Link pending
0001564590-18-003515-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g2018022715174106224988.jpg Edgar Link pending
g2018022715174131524989.jpg Edgar Link pending
g2018022715174133724990.jpg Edgar Link pending
g2018022715174134824991.jpg Edgar Link pending
g2018022715174136224992.jpg Edgar Link pending
g2018022715174137224993.jpg Edgar Link pending
g2018022715174143524994.jpg Edgar Link pending
g2018022715174144424995.jpg Edgar Link pending
g2018022715174145524996.jpg Edgar Link pending
g2018022715174148924997.jpg Edgar Link pending
g2018022715174150224998.jpg Edgar Link pending
g2018022715175924925000.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vtvt-10k_20171231.htm Edgar Link pending
vtvt-20171231.xml Edgar Link completed
vtvt-20171231.xsd Edgar Link pending
vtvt-20171231_cal.xml Edgar Link unprocessable
vtvt-20171231_def.xml Edgar Link unprocessable
vtvt-20171231_lab.xml Edgar Link unprocessable
vtvt-20171231_pre.xml Edgar Link unprocessable
vtvt-ex1017_693.htm Edgar Link pending
vtvt-ex1018_692.htm Edgar Link pending
vtvt-ex1019_691.htm Edgar Link pending
vtvt-ex1020_690.htm Edgar Link pending
vtvt-ex211_6.htm Edgar Link pending
vtvt-ex231_7.htm Edgar Link pending
vtvt-ex311_11.htm Edgar Link pending
vtvt-ex312_9.htm Edgar Link pending
vtvt-ex321_8.htm Edgar Link pending
vtvt-ex322_10.htm Edgar Link pending
vtvt-ex42_694.htm Edgar Link pending